A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)
The NILEAD trial represents a significant advancement in therapeutic development for Alzheimer's disease by investigating nilotinib, a tyrosine kinase inhibitor originally approved for chronic myeloid leukemia, in the context of Alzheimer's disease pathology. This study leverages the growing understanding of the role played by the c-Abl (Abelson tyrosine kinase) pathway in neurodegenerative processes["@novel2024"].
Alzheimer's disease affects approximately 50 million people worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options. Despite significant advances in understanding AD pathophysiology, there remain no approved disease-modifying therapies that can halt or reverse the underlying neurodegenerative process["@alzheimers2023"].
A Multicenter, Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)
The NILEAD trial represents a significant advancement in therapeutic development for Alzheimer's disease by investigating nilotinib, a tyrosine kinase inhibitor originally approved for chronic myeloid leukemia, in the context of Alzheimer's disease pathology. This study leverages the growing understanding of the role played by the c-Abl (Abelson tyrosine kinase) pathway in neurodegenerative processes["@novel2024"].
Alzheimer's disease affects approximately 50 million people worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options. Despite significant advances in understanding AD pathophysiology, there remain no approved disease-modifying therapies that can halt or reverse the underlying neurodegenerative process["@alzheimers2023"].
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT05143528 |
| Phase | PHASE3 |
| Status | NOT_YET_RECRUITING |
| Sponsor | KeifeRx, LLC |
| Enrollment | 1275 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2022-02-01 00:00:00 |
| Completion Date | 2026-06-01 00:00:00 |
| Last Updated | 2021-12-03 00:00:00 |
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].
The c-Abl (Abelson tyrosine kinase) pathway represents an emerging therapeutic target in Alzheimer's disease. Originally studied primarily in the context of cancer biology and Parkinson's disease, recent research has demonstrated that c-Abl is also activated in AD brains and contributes to disease pathogenesis through several mechanisms:
Amyloid-Beta Toxicity: c-Abl is activated by amyloid-beta exposure in neurons, creating a vicious cycle where Aβ promotes c-Abl activation, which in turn exacerbates neuronal dysfunction. This activation contributes to synaptic toxicity and impaired neuronal survival[@hebron2013].
Tau Pathology: c-Abl phosphorylates tau protein at multiple tyrosine residues, potentially promoting tau aggregation and the formation of neurofibrillary tangles. This represents a direct link between c-Abl activation and one of the core pathological hallmarks of AD.
Autophagy Dysfunction: c-Abl hyperactivation impairs autophagy, the cellular recycling process responsible for clearing damaged proteins and organelles. This impairment contributes to the accumulation of toxic protein aggregates, including amyloid-beta and tau[@karim2021].
Synaptic Dysfunction: c-Abl activation disrupts synaptic plasticity and function, contributing to the cognitive decline characteristic of AD. The kinase affects NMDA receptor signaling and dendritic spine morphology.
Nilotinib (Tasigna) is a BCR-Abl tyrosine kinase inhibitor originally developed and approved for the treatment of chronic myeloid leukemia (CML). The drug potently inhibits c-Abl at concentrations significantly lower than those used in oncology, making it suitable for CNS applications[@pagan2020].
Mechanisms of Action in AD:
Clinical Development History:
The NILEAD trial tests the hypothesis that nilotinib can slow disease progression in early AD by:
This represents a disease-modifying approach that targets a fundamentally different pathway than amyloid-targeting antibodies currently in development.
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].
Key features of the Phase 3 design include:
Key inclusion criteria for NILEAD:
Key exclusion criteria:
Participants are randomized using a centralized interactive web response system (IWRS) to ensure allocation concealment. The randomization schedule is stratified by baseline disease severity (MCI vs mild dementia) and apolipoprotein E (ApoE) ε4 carrier status to ensure balanced distribution of these prognostic factors across treatment arms.
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may[@future2024]:
NILEAD occupies a unique position among AD trials by targeting a fundamentally different pathway than amyloid-targeting therapies:
| Trial Type | Target | Examples | Status |
|------------|--------|----------|--------|
| Amyloid antibodies | Aβ plaques | Lecanemab, Donanemab | Approved/Phase 3 |
| Tau vaccines | Tau tangles | ACI-35, Lu AF87903 | Phase 2/3 |
| c-Abl inhibitor | c-Abl kinase | Nilotinib (NILEAD) | Phase 3 |
| Neuroprotective | Multiple | AL-108, Davunetide | Completed |
The success of nilotinib would provide a completely novel mechanism of action and potentially help patients who have not responded to or cannot receive amyloid-targeting therapies.
The c-Abl (Abelson tyrosine kinase) protein is a non-receptor tyrosine kinase with multiple regulatory domains:
c-Abl Structure:
|---------|---------|---------|---------|
| SH3 | SH2 | SH1 | F-actin |
| | | Kinase | binding |
|---------|---------|---------|---------|
|
Regulatory
Key Domains:
c-Abl participates in normal cellular processes:
| Function | Mechanism | Outcome |
|----------|-----------|---------|
| Cell adhesion | Integrin signaling | Migration, attachment |
| Actin dynamics | Cytoskeletal regulation | Shape, movement |
| Cell cycle | CDK regulation | Proliferation |
| DNA repair | ATM activation | Genomic stability |
| Autophagy | ULK1 phosphorylation | Protein clearance |
In neurodegeneration, c-Abl is activated by:
Key substrate proteins:
| Substrate | Modification | Consequence |
|-----------|--------------|------------|
| Tau | Y394, Y197 | Aggregation |
| α-Synuclein | Y39 | Toxicity |
| parkin | Y143 | Mitochondrial dysfunction |
| APP | Y682 | Amyloid processing |
| PSD-95 | S573 | Synaptic damage |
Autophagy is the cellular recycling process:
mTOR inhibition or ULK1 activation
↓
Phosphatidylinositol 3-phosphate production
↓
Isolation membrane formation
↓
Cargo recognition (p62/SQSTM1)
↓
Autophagosome-lysosome fusion
↓
Degradation and recycling
Nilotinib enhances autophagy through:
Critical aspect of nilotinib in neurodegeneration:
| Parameter | Cancer Dose | Neurodegeneration Dose |
|-----------|------------|------------------------|
| Daily dose | 400-600 mg | 150-300 mg |
| Cmax | 2-5 μM | 0.2-0.5 μM |
| CSF penetration | Limited | Adequate |
| Duration | Continuous | Intermittent |
The therapeutic rationale:
Absorption:
| Interaction | Effect | Management |
|-------------|-------|------------|
| CYP3A4 inhibitors | Increased levels | Dose reduction |
| CYP3A4 inducers | Reduced levels | Avoid |
| Anticoagulants | Bleeding risk | Monitor |
| Myelosuppressive | Additive | Avoid |
Cerebrospinal fluid biomarkers include:
| Biomarker | Change with Nilotinib | Interpretation |
|-----------|---------------------|----------------|
| Aβ40 | Increase | Enhanced clearance |
| Aβ42 | Increase | Enhanced clearance |
| Total tau | Decrease | Neuroprotection |
| p-tau | Decrease | Reduced pathology |
| NfL | Decrease | Reduced neurodegeneration |
| α-Synuclein | Decrease | Enhanced clearance |
Blood-based biomarkers under investigation:
| Biomarker | Matrix | Feasibility |
|----------|--------|-------------|
| Total tau | Plasma | High |
| NfL | Plasma | High |
| p-tau181 | Plasma | High |
| Aβ40/42 | Plasma | Moderate |
Imaging endpoints include:
| Adverse Event | Frequency | Grade 3/4 |
|---------------|----------|-----------|
| Nausea | 25% | <1% |
| Fatigue | 20% | <1% |
| Headache | 15% | <1% |
| Dry mouth | 12% | <1% |
| Neutropenia | 8% | 2% |
| QT prolongation | 5% | 1% |
Required monitoring in NILEAD:
Excluded conditions:
| Drug | Mechanism | Stage | Indication |
|------|-----------|-------|-----------|
| Nilotinib | c-Abl inhibitor | Phase 3 | AD, PD |
| Rapamycin | mTOR inhibitor | Phase 2 | AD |
| Lithium | IMPase inhibitor | Phase 2 | AD |
| Valproic acid | HDAC inhibitor | Phase 2 | AD |
| Trehalose | Autophagy inducer | Preclinical | Multiple |
NILEAD design supports:
Alternative approval pathways:
Previous nilotinib indications:
Potential combinations with nilotinib:
Future trial designs may:
Broader applications: